Compared to the GLP-1 receptor agonist semaglutide and placebo, tirzepatide demonstrated superior reductions in HbA1c (2.05%) and body weight (11.2kg) over 28 weeks
The results were published in the American Journal of Physiology, Heart and Circulatory Physiology
West S, Scragg J, Aveyard P, Oke JL, Willis L, Haffner SJP, Knight H, Wang D, Morrow S, Heath L, Jebb SA, Koutoukidis DA
46 Moreover, patients with moderate to advanced hepatic fibrosis are at increased risk of cirrhosis, 7,8 which justifies the need for pharmacotherapy in patients with MASH and advanced fibrosis
La analista cientfica Elisa Loch Razzera presenta los principales temas tratados en el Congreso Brasileo de Nutricin Parenteral y Enteral/SBNPE 2025, recopilando las actualizaciones cientficas ms relevantes y sus implicaciones para la prctica en nutricin clnica